Pick Any Acute Disease Use Guillain-Barré Syndrome ✓ Solved

Pick Any Acute Disease Use Guillain Barré Syndromemust Use The Sample

Pick any acute disease: Use Guillain-Barré syndrome. Must use the sample template for your SOAP note. Follow the SOAP note rubric as a guide. Use APA format and include a minimum of two scholarly citations. The SOAP notes will be uploaded to Moodle and submitted through Turnitin. Copying and pasting from websites or textbooks will not be accepted or tolerated. The use of templates is permitted, but the patient history, chief complaint, HPI, assessment, and plan should be your own work and individualized based on the fictional patient you create.

Sample Paper For Above instruction

Introduction

Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyneuropathy characterized by rapid-onset muscle weakness and potential paralysis. It is considered a medical emergency that requires prompt diagnosis and management. The following SOAP note documents a fictional patient case to illustrate the assessment and care plan for GBS, adhering to the stipulated guidelines, incorporating scholarly sources, and maintaining originality.

Subjective

Chief Complaint (CC): "I've been experiencing weakness and numbness in my legs and arms that started suddenly."

History of Present Illness (HPI): The patient, a 45-year-old male, reports that five days ago, he began feeling tingling sensations in his toes, which rapidly progressed to weakness in both legs. Over the past two days, he has noticed difficulty walking, with increasing fatigue and muscle weakness. No history of recent trauma, infections, or illnesses. He reports difficulty swallowing and some mild shortness of breath. The symptoms have been steadily worsening but no loss of consciousness or incontinence.

Past Medical History: No significant previous health issues; no history of neurological disorders.

Medications: None regularly.

Allergies: No known drug allergies.

Family and Social History: No family history of neurological diseases. He works as an accountant, non-smoker, occasional alcohol use, no illicit drug use.

Objective

  • Vital Signs: Blood pressure 130/80 mmHg, heart rate 88 bpm, respiratory rate 16 bpm, temperature 98.6°F, oxygen saturation 98% on room air.
  • General: Alert but appears tired and weak.
  • Neurological Examination:
    • Motor: Decreased strength in bilateral lower extremities (3/5) and mild weakness in upper extremities (4/5).
    • Sensation: Decreased vibration and pinprick sensation in feet and hands.
    • Reflexes: Absent deep tendon reflexes in the knees and ankles.
    • Cranial Nerves: Mild dysarthria, diminished gag reflex.
    • Coordination: No ataxia noted.

Assessment

The patient presents with symptoms indicative of Guillain-Barré syndrome, including progressive weakness, areflexia, and sensory disturbances. The rapid progression over days and cranial nerve involvement supports this diagnosis. Differential diagnoses considered include transverse myelitis, multiple sclerosis, and botulism, but clinical features favor GBS. Diagnostic tests such as nerve conduction studies and cerebrospinal fluid analysis are planned to confirm the diagnosis.

Plan

  1. Initiate hospitalization for close monitoring of respiratory function and neurological status.
  2. Order diagnostic tests:
    • Electromyography (EMG) and nerve conduction studies to assess demyelination.
    • Lumbar puncture for cerebrospinal fluid (CSF) analysis to identify elevated protein levels with normal cell count (albuminocytologic dissociation).
  3. Begin treatment with intravenous immunoglobulin (IVIG) at a dose of 2 g/kg over 2-5 days.
  4. Monitor respiratory function closely; prepare for mechanical ventilation if necessary.
  5. Supportive care:
    • Physical and occupational therapy to maintain muscle strength and prevent complications.
    • Deep vein thrombosis prophylaxis due to immobility.
  6. Educate patient and family about the disease course, importance of adherence to treatment, and potential for recovery.
  7. Schedule follow-up assessments to monitor progress and manage complications.

Discussion

Guillain-Barré syndrome is an autoimmune disorder that often follows infections such as Campylobacter jejuni, cytomegalovirus, or Epstein-Barr virus (Hugosson et al., 2019). The pathogenesis involves immune-mediated attack on peripheral nerves, leading to demyelination or axonal damage. Typical onset includes weakness that ascends from lower limbs and may involve cranial nerves, leading to facial weakness and dysphagia (Kaabay et al., 2021). Early recognition and prompt intervention with IVIG or plasma exchange significantly impact outcomes, reducing disability and mortality.

Monitoring respiratory function is crucial because of the risk of respiratory failure, which often necessitates ventilatory support. The diagnostic hallmark in CSF analysis is albuminocytologic dissociation—elevated protein with a normal cell count—though it may not be evident in the first week (Hugosson et al., 2019). Electrophysiological studies aid in the subtyping and severity assessment, guiding treatment options. Rehabilitation plays a critical role in recovery, emphasizing physical therapy to regain strength and function (Green et al., 2020).

The prognosis varies; early treatment improves recovery chances, but some patients may experience residual weakness or sensory deficits. Understanding the immune-mediated mechanisms underlying GBS emphasizes the need for timely diagnosis, appropriate management, and comprehensive supportive care (Khan et al., 2020). Ongoing research focuses on immunomodulatory therapies and predicting outcomes based on early clinical markers (Hugosson et al., 2019).

Conclusion

Guillain-Barré syndrome remains a significant neurological emergency that requires prompt recognition and intervention. The case illustrates typical presentation, diagnostic approach, and management strategies aimed at preventing respiratory failure and optimizing functional recovery. Continued research into its pathogenesis and treatment will enhance patient outcomes and improve survival rates.

References

Hugosson, J., Andersen, H. F., & Vollset, S. E. (2019). Epidemiology of Guillain-Barré syndrome: A population-based study. Journal of Neuroimmunology, 340, 577180. https://doi.org/10.1016/j.jneuroimmunol.2019.577180

Kaabay, S., Sheikh, M., & Osei, T. (2021). Diagnosis and management of Guillain-Barré syndrome: A review. World Journal of Clinical Cases, 9(8), 1776–1790. https://doi.org/10.12998/wjcc.v9.i8.1776

Green, S., Karamyan, D., & Kumar, S. (2020). Rehabilitation strategies in Guillain-Barré syndrome. Neurological Rehabilitation, 37(2), 99-106. https://doi.org/10.1080/09638288.2020.1713234

Khan, S., Bhattacharya, A., & Bhattacharjee, T. (2020). Advances in understanding Guillain-Barré syndrome. Current Treatment Options in Neurology, 22(7), 28. https://doi.org/10.1007/s11940-020-00667-4

Hugosson, J., Andersen, H. F., & Vollset, S. E. (2019). Epidemiology of Guillain-Barré syndrome: A population-based study. Journal of Neuroimmunology, 340, 577180. https://doi.org/10.1016/j.jneuroimmunol.2019.577180

Johnston, M. V., & McLellan, T. (2019). Pathophysiology of Guillain-Barré syndrome. Nature Reviews Neurology, 15(8), 463-477. https://doi.org/10.1038/s41582-019-0249-1

Schoemaker, N., van Schaik, I. N., & van Doorn, P. A. (2021). Treatment and prognosis of Guillain-Barré syndrome. Nature Reviews Neurology, 17(2), 112-122. https://doi.org/10.1038/s41582-020-00444-0

Wakerley, B. R., Jamous, S., & Yuki, N. (2019). Guillain-Barré syndrome. Neurologic Clinics, 37(4), 949-964. https://doi.org/10.1016/j.ncl.2019.07.004

Jacob, S., & Bhardwaj, S. (2022). Emerging therapies in Guillain-Barré syndrome. Therapeutic Advances in Neurological Disorders, 15, 17562864221091975. https://doi.org/10.1177/17562864221091975

Related Assignments